A Phase 2B, Open-Label Study to Explore Tissue Histopathology Following Subcutaneous Injection of Collagenase Clostridium Histolyticum Using An Abdominoplasty Model
Latest Information Update: 14 Apr 2022
At a glance
- Drugs Collagenase clostridium histolyticum (Primary)
- Indications Cellulite
- Focus Therapeutic Use
- Sponsors Endo Pharmaceuticals
Most Recent Events
- 12 Nov 2020 Status changed from recruiting to completed.
- 28 Sep 2020 Planned End Date changed from 1 Sep 2020 to 1 Oct 2020.
- 28 Sep 2020 Planned primary completion date changed from 1 Sep 2020 to 1 Oct 2020.